Zobrazeno 1 - 4
of 4
pro vyhledávání: '"MJ Soto Pino"'
Autor:
R Morón Romero, LJ Martinez, CL Dávila Fajardo, X Diaz Villamarin, M Valle Corpas, D Blanquez Martinez, MJ Soto Pino, J Cabeza Barrera, E Raya Alvarez, Mdc Gonzalez Medina
Publikováno v:
European Journal of Hospital Pharmacy. 23:A142.1-A142
Background Tocilizumab (TCZ) is a humanised monoclonal antibody inhibitor of interleukin 6 receptor, indicated in combination with methotrexate in the treatment of rheumatoid arthritis (RA) in patients with inadequate response or intolerance to prior
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc0ea85ffa75f264d27ba6c2f09d6366
https://doi.org/10.1136/ejhpharm-2016-000875.321
https://doi.org/10.1136/ejhpharm-2016-000875.321
Autor:
Luis Javier Martinez-Gonzalez, M Núñez, Mdc González-Medina, A Gómez-Martín, Cristina Lucía Dávila-Fajardo, I Casas-Hidalgo, J Cabeza-Barrera, MJ Soto-Pino, X Díaz-Villamarín
Publikováno v:
European Journal of Hospital Pharmacy. 23:A189.1-A189
Background The engagement of FcGRs by TNF antagonists could affect macrophage mediated clearance of immune complexes. Purpose The aim of our study was to explore the potential role of FcGR2A genetic polymorphism as a predictor of tocilizumab efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e3c1b948925a5b1a2fbbd0a69036ed4
https://doi.org/10.1136/ejhpharm-2016-000875.427
https://doi.org/10.1136/ejhpharm-2016-000875.427
Autor:
Mdc González-Medina, E Sánchez-Yáñez, MJ Soto-Pino, I Casas-Hidalgo, Luis Javier Martinez-Gonzalez, Cristina Lucía Dávila-Fajardo, A Gómez-Martín, M Domínguez-Cantero, J Cabeza-Barrera, X Díaz-Villamarín
Publikováno v:
European Journal of Hospital Pharmacy. 23:A188.3-A189
Background Interleukin (IL)-6 is involved in the pathogenesis of rheumatoid arthritis (RA) via its broad effects on immune and inflammatory responses. Sustained IL-6 activity can cause tissue damage in different tissues. Previous studies have shown t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c119b80a50e88e2608fcda6d7f5de69f
https://doi.org/10.1136/ejhpharm-2016-000875.426
https://doi.org/10.1136/ejhpharm-2016-000875.426
Autor:
J Cabeza-Barrera, E Sánche-Gómez, MJ Soto-Pino, Cristina Lucía Dávila-Fajardo, Mdc González-Medina, Luis Javier Martinez-Gonzalez, I Casas-Hidalgo, A Acuña, A Gómez-Martín, X Díaz-Villamarín
Publikováno v:
European Journal of Hospital Pharmacy. 23:A188.2-A188
Background Tocilizumab (TCZ) is a humanised monoclonal antibody inhibitor of interleukin-6 receptor, indicated in combination with methotrexate in the treatment of rheumatoid arthritis (RA) in patients with inadequate response or intolerance to prior
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca8b63754fdddf1fd66acd4c0833d225
https://doi.org/10.1136/ejhpharm-2016-000875.425
https://doi.org/10.1136/ejhpharm-2016-000875.425